The application of a drug candidate for ALS treatment was issued as a patent

The patent for the use of SO-002, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS) that our company is developing, “a therapeutic or prophylactic agent for amyotrophic lateral sclerosis” (Patent No. 7660827), has been granted.
This is an essential milestone for SOCIUM Inc., which continues to promote innovation in drug discovery and pursue the resolution of unmet medical needs. We are committed to improving the lives of those affected by ALS, and this patent certificate is a testament to our ongoing efforts and dedication in this field.

This patent was applied for and granted under the guidance of Mr. Arimichi Ito, a patent attorney at TMI Associates. We would like to express our gratitude here.

About SOCIUM Inc.
SOCIUM Inc. is a venture company that discovers drug seeds, especially drug candidates for the treatment of rare diseases, by utilizing drug repositioning(*1) technology. With the vision of “providing medicine to those without it, and providing medicine to those for whom it is ineffective”, we are working to overcome the unmet medical needs of patients. For more information about our unique drug discovery approach and our progress, please refer to the relevant sections of our website (https://socium.co.jp/drug_discovery/ ; https://socium.co.jp/2024/09/17/2024091701/).

(*1) Drug repositioning
To discover new applicable indications for existing drugs on the market or drugs in development. Also, to discover existing drugs (known but new chemical structures) that show efficacy against the target disease.

For inquiries regarding this matter, please contact
SOCIUM Inc.
5th, 6th, and 7th floors of Waterfront Center Annex, National Institute of Advanced Industrial Science and Technology (AIST)
2-4-7 Aomi, Koto-ku, Tokyo, Japan 1350064
https://socium.co.jp
E-mail: contact@socium.co.jp